Targeting transforming growth factor-β signaling
Authors:
- 1 November 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 19 (6) , 579-585
Abstract
Purpose of review Most cancers are characterized by excessive transforming growth factor-β production by tumors, which can promote tumor growth and mediate epithelial-to-mesenchymal transition. Transforming growth factor-β also has the ability to overproduce extracellular matrix components in response to injury and other stimuli. There are many strategies undergoing current evaluation for inhibiting the deleterious biological effects of transforming growth factor-β by disrupting its signaling at various levels. The current review focuses on the recent advances made in this area, and the potential of these strategies in the clinical treatment of cancer and fibrosis. Recent findings Four main strategies used most recently for disrupting transforming growth factor-β signaling are brought into focus in this review: inhibition or sequestration of the transforming growth factor-β protein ligands, inhibition of transforming growth factor-β receptor kinase activity, inhibition of SMAD signaling downstream of transforming growth factor-β kinase activity and restoration of antitumor immunity upon transforming growth factor-β inhibition. Various techniques currently used to employ these four strategies are discuussed. Summary Several lines of evidence suggest that altered transforming growth factor-β signaling contributes to tumor progression and metastasis as well as development of fibrosis. Accumulating data from preclinical and clinical studies indicate that antagonizing aberrant transforming growth factor-β signaling is a promising novel therapeutic approach in cancer and fibrotic disorders.Keywords
This publication has 30 references indexed in Scilit:
- Inhibition of Transforming Growth Factor β Signaling Reduces Pancreatic Adenocarcinoma Growth and InvasivenessMolecular Pharmacology, 2007
- Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progressionJournal of Clinical Investigation, 2007
- Pirfenidone inhibits TGF-β expression in malignant glioma cellsBiochemical and Biophysical Research Communications, 2007
- Inhibition of Transforming Growth Factor-β1–induced Signaling and Epithelial-to-Mesenchymal Transition by the Smad-binding Peptide Aptamer Trx-SARAMolecular Biology of the Cell, 2006
- Intracellular TGF-β Receptor Blockade Abrogates Smad-Dependent Fibroblast Activation In Vitro and In VivoJournal of Investigative Dermatology, 2006
- Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-β Type I Receptor KinaseIn vivoClinical Cancer Research, 2006
- Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine in patients with advanced gliomaCancer Gene Therapy, 2006
- Blockade of transforming growth factor-β signaling in tumor-reactive CD8+ T cells activates the antitumor immune response cycleMolecular Cancer Therapeutics, 2006
- Targeted tumor therapy with the TGF-β2 antisense compound AP 12009Cytokine & Growth Factor Reviews, 2006
- Inhibition of TGF-beta1 expression in human peritoneal mesothelial cells by pcDU6 vector-mediated TGF-beta1 shRNANephrology, 2006